Efficacy of an early first dose of whole-cell pertussis vaccine in infants for the prevention of IgE-mediated food allergy: A randomised controlled trial

Read the full article

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Evidence from mechanistic and observational studies suggests that replacing the first acellular pertussis (aP) vaccine dose in early infancy with a whole-cell pertussis (wP)-containing vaccine may reduce the risk of developing IgE-mediated food allergy during childhood.

Objective

We aimed to determine if a dose of wP at approximately 6 weeks old, in lieu of aP vaccine, could reduce the incidence of food allergy in infants.

Methods

In this multicentre, randomised, participant and outcome assessor-blinded, parallel, two-stage, Bayesian adaptive trial we assigned Australian infants to one of two pertussis vaccination schedules. These consisted of either a standard homologous priming with a hexavalent combination aP vaccine (diphtheria, tetanus, aP, hepatitis B, inactivated poliovirus types 1, 2, and 3, and Haemophilus influenzae type b; DTaP-HepB-IPV-Hib) at approximately 6 weeks, 4 months and 6 months old (‘aP-only’ schedule), or a first dose of a WHO-prequalified pentavalent wP combination vaccine (DTwP-HepB-Hib; Pentabio®, PT Bio Farma Indonesia) at approximately 6 weeks old, followed by hexavalent aP combination vaccine at approximately 4 months and 6 months old (‘mixed wP/aP’ schedule). The primary outcome was physician-confirmed food allergy by age 12 months requiring both evidence of sensitisation and compatible symptoms in response to either incidental or medically supervised oral food challenge. The initial target sample size was 3,000 enrolments to provide approximately 85% power to detect a policy-relevant 3 percentage point reduction in the risk of the primary outcome.

Results

A total of 972 infants were enrolled, 486 in each study arm. Of these, 26 of 486 (5.3%) assigned to the aP-only group and 31 of 486 (6.4%) assigned to the mixed wP/aP schedule met the primary endpoint definition. The posterior median difference (95% credible interval) in food allergy among recipients of the mixed wP/aP schedule compared to recipients of the aP-only schedule was 0.01 (−0.02, 0.04; probability [<0] 0.25). There were six serious adverse events (SAEs) among children receiving the aP-only group versus 12 among children receiving the mixed wP/aP schedule; one SAE (hospitalisation for irritability; length of stay < 48 hours) was deemed related to wP vaccine. The trial was stopped early owing to operational reasons.

Conclusions

There is a low probability of a policy-relevant reduction in food allergy in infants receiving mixed wP/aP versus aP-only pertussis vaccine schedules. Funded by the National Health and Medical Research Council of Australia; ANZCTR number, ACTRN12617000065392p.

Clinical implications

An early first dose of wP is unlikely to afford a policy-relevant reduction in the probability of developing food allergy, eczema or atopic sensitisation in infants.

Capsule summary

An early first dose of a 5-in-1 wP combination vaccine is reasonably tolerated but would not be expected to have a material impact on the prevalence of food allergy in infants.

Article activity feed